<DOC>
	<DOCNO>NCT00837291</DOCNO>
	<brief_summary>This study test effectiveness CF101 treating symptom osteoarthritis ( OA ) knee . Eligible patient give either CF101 match placebo tablet symptom evaluate 12 week treatment period .</brief_summary>
	<brief_title>A Study Efficacy Safety CF101 Patients With Osteoarthritis Knee</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group study patient knee OA randomize either CF101 1 mg match placebo tablet every 12 hour follow 12 week treatment . For patient bilateral knee involvement , 1 knee select evaluation , namely , severely involved knee meet study criterion ( `` index knee '' ) . Screening examination occur within 1 month prior dose . Washout non-specific non-steroidal anti-inflammatory drug ( nsNSAIDs ) cyclo-oxygenase-2 ( COX-2 ) inhibitor occur prior dose , must follow requalification dose . Disease activity assess use change baseline Patient 's Global Assessment ( PGA ) Investigator 's Global Assessment ( IGA ) score , Western Ontario McMaster Universities Osteoarthritis ( WOMAC ) index subscales pain , physical function , stiffness , accord Outcome Measures Rheumatology Clinical Trials-Osteoarthritis Research Society International ( OMERACT-OARSI ) criterion . Assessments take place Screening , Baseline ( Week 0 ) , Weeks 2 , 4 , 8 , 12 , 14 .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Males female age 40 year Clinical evidence knee OA , indicate : Pain require treatment NSAID coxib medication analgesia least 6 month prior screen visit , Pain require treatment NSAID coxib medication analgesia majority day precede month Radiographic evidence knee OA , indicate finding KellgrenLawrence Grade 2 3 within 1 year prior screen visit2 American College Rheumatology functional class I , II , III3 WOMAC pain subscale score â‰¥40 mm baseline WOMAC function subscale score &gt; 20 mm baseline PGA &gt; 10 mm baseline In Investigator 's opinion , ability understand nature study hazard participation , communicate satisfactorily Investigator participate , comply , requirement entire protocol Negative screening serum pregnancy test female patient childbearing potential Females childbearing potential must utilize , throughout course trial , 2 method contraception deem adequate Investigator ( example , oral contraceptive pill plus barrier method ) All aspect protocol explain write informed consent obtain Predominant patellofemoral disease Concomitant local systemic inflammatory arthropathy could confound evaluation knee Ipsilateral hip extremity disease could confound evaluation knee History clinical significant trauma surgery index knee Arthroscopy index knee within 6 month prior screen visit Corticosteroid , hyaluronic acid , intraatricular injection index knee within 3 month prior screen visit Use chondroitin sulfate and/or glucosamine , diacerin , within 2 week prior screen visit Concomitant requirement NSAID , coxib medication , opioid analgesic ( acetaminophen allow ) Use systemic corticosteroid &gt; 10 mg/d prednisone , equivalent Presence history uncontrolled arterial hypertension symptomatic hypotension Significant cardiac arrhythmia conduction block , congestive heart failure , evidence clinically significant heart disease ; clinically significant finding screen electrocardiogram ( ECG ) Hemoglobin level &lt; 10.0 gm/dL screen visit White blood cell count &lt; 3000/mm3 screen visit Platelet count &lt; 125,000/mm3 screen visit Serum creatinine level outside central laboratory 's normal limit screen visit Liver aminotransferase ( ALT and/or AST ) level great upper limit normal screening visit Known suspect immunodeficiency human immunodeficiency virus positivity Pregnancy , lactation , inadequate contraception judge Investigator Participation another investigational drug vaccine trial concurrently within 30 day prior screen History drug alcohol dependence History malignancy within past 5 year ( exclude excise basal squamous cell carcinoma skin ) Diagnosis Parkinson 's Disease Significant acute chronic medical psychiatric illness , judgment Investigator , could compromise patient safety , limit patient 's ability complete study , and/or compromise objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>CF101</keyword>
</DOC>